Harnessing self-reactivity in cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Advances in identifying human tumor antigens at the molecular level have enhanced understanding of cancer immunity.
• The presence of self-reactive T cells in cancer patients suggests a dormant self-reactive T-cell repertoire in humans.
• These autoreactive T cells, typically associated with autoimmune disease, hold potential for cancer immunotherapy.

Purpose of the Study:

• To explore the potential of utilizing self-reactive T cells for anti-tumor immune responses.
• To identify suitable targets for a self-directed anti-tumor immune response.
• To investigate strategies for overcoming peripheral tolerance to self-antigens.

Main Methods:

• Identification of human tumor antigens.
• Analysis of T-cell repertoire reactivity to self-proteins.
• Investigation of potential targets including overexpressed proteins, differentiation antigens, and developmental proteins.
• Strategies to overcome non-deletional peripheral tolerance.

Main Results:

• Self-reactive T cells exist in normal individuals and can recognize tumor antigens.
• Overexpressed proteins, tissue-specific differentiation antigens, and aberrantly expressed developmental proteins are potential targets.
• Targeting subdominant and cryptic determinants may maximize anti-tumor effects while minimizing damage to normal tissues.

Conclusions:

• Self-reactive T cells represent a valuable, yet largely untapped, resource for cancer immunotherapy.
• Careful selection of tumor antigens and determinants is crucial for effective and safe self-directed anti-tumor immunity.
• Overcoming peripheral tolerance may be necessary to fully leverage self-reactive T cells in cancer treatment.